AR021981A1 - Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero - Google Patents
Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un terceroInfo
- Publication number
- AR021981A1 AR021981A1 ARP990106668A ARP990106668A AR021981A1 AR 021981 A1 AR021981 A1 AR 021981A1 AR P990106668 A ARP990106668 A AR P990106668A AR P990106668 A ARP990106668 A AR P990106668A AR 021981 A1 AR021981 A1 AR 021981A1
- Authority
- AR
- Argentina
- Prior art keywords
- party
- deviation
- pharmaceutical composition
- avoid
- oral route
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9816309A FR2787715B1 (fr) | 1998-12-23 | 1998-12-23 | Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021981A1 true AR021981A1 (es) | 2002-09-04 |
Family
ID=9534386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106668A AR021981A1 (es) | 1998-12-23 | 1999-12-22 | Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1140011A1 (fr) |
| AR (1) | AR021981A1 (fr) |
| AU (1) | AU1663900A (fr) |
| CO (1) | CO5150153A1 (fr) |
| FR (1) | FR2787715B1 (fr) |
| WO (1) | WO2000038649A1 (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| DK1041987T3 (da) | 1997-12-22 | 2006-08-21 | Euro Celtique Sa | Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| RS50407B (sr) | 2000-02-08 | 2009-12-31 | Euro-Celtique S.A., | Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika |
| ES2361148T3 (es) | 2001-05-11 | 2011-06-14 | Endo Pharmaceuticals Inc. | Forma de dosificación de opioides de liberación controlada resistente al abuso. |
| EP1406630A1 (fr) | 2001-07-06 | 2004-04-14 | Endo Pharmaceuticals Inc. | Administration parenterale de 6-hydroxy-oxymorphone destinee a etre utilisee en tant qu'analgesique |
| US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| MXPA04001210A (es) | 2001-08-06 | 2004-07-08 | Euro Celtique Sa | Formulaciones de agonista opioide con antagonista liberable y aislado. |
| FR2829933B3 (fr) * | 2001-09-21 | 2004-03-12 | Ellipse Pharmaceuticals | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu |
| CN102813654A (zh) | 2002-04-05 | 2012-12-12 | 欧洲凯尔蒂克公司 | 含有羟氢可待酮和烯丙羟吗啡酮的药物制剂 |
| PT1551372T (pt) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | Subunidade de sequestração e composições e métodos relacionados |
| MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
| KR20130116378A (ko) * | 2004-02-17 | 2013-10-23 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법 |
| EP1765292B1 (fr) | 2004-06-12 | 2017-10-04 | Collegium Pharmaceutical, Inc. | Formulations de prévention des abus |
| WO2006002836A1 (fr) * | 2004-07-01 | 2006-01-12 | Losan Pharma Gmbh | Compositions effervescentes de somniferes |
| EP1702558A1 (fr) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Procédé et dispositif pour évaluer la fonction de l'activité intestinale |
| EP2526932B1 (fr) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Composition pharmaceutique |
| FR2904225B1 (fr) * | 2006-07-28 | 2010-08-13 | Bouchara Recordati | Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees |
| PL2187873T3 (pl) | 2007-08-13 | 2019-01-31 | Abuse Deterrent Pharmaceutical Llc | Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| TW201006473A (en) * | 2008-08-13 | 2010-02-16 | Orient Pharma Co Ltd | Bi-layer medicine tablet containing Zaleplon |
| WO2010103039A1 (fr) | 2009-03-10 | 2010-09-16 | Euro-Celtique S.A. | Compositions pharmaceutiques à libération immédiate comportant de l'oxycodone et du naloxone |
| FR2949062B1 (fr) * | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| FR2962331B1 (fr) * | 2010-07-06 | 2020-04-24 | Ethypharm | Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre |
| FR2962550B1 (fr) * | 2010-07-06 | 2013-06-14 | Ethypharm Sa | Methode pour lutter contre la soumission chimique, utilisation d'agent colorant pour lutter contre la soumission chimique et composition pharmaceutique permettant la mise en oeuvre de la methode |
| FR2968995B1 (fr) * | 2010-12-16 | 2013-03-22 | Sanofi Aventis | Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage |
| FR2968992B1 (fr) * | 2010-12-16 | 2013-02-08 | Sanofi Aventis | Comprime pharmaceutique orodispersible a base de zolpidem |
| US11571390B2 (en) | 2013-03-15 | 2023-02-07 | Othemo Life Sciences, Inc. | Abuse deterrent compositions and methods of use |
| CA2918004C (fr) | 2013-07-23 | 2018-11-20 | Euro-Celtique S.A. | Combinaison d'oxycodone et de naloxone pour utilisation dans le traitement de la douleur chez des patients souffrant de douleur et d'une maladie entrainant une dysbiose intestinale et/ou l'augmentation du risque de translocation bacterienne intestinale |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| GB201316857D0 (en) * | 2013-09-23 | 2013-11-06 | Buckley Howard | Composition for the oral delivery of compounds |
| WO2015095391A1 (fr) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Comprimé extrudé anti-abus à libération prolongée |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2016010771A1 (fr) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus à libération immédiate |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| EP3209282A4 (fr) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Forme galénique anti-abus de remplissage de liquide à libération prolongée |
| WO2017222575A1 (fr) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Procédé de préparation de formulations orales dissuasives d'abus plus stables |
| US20220202742A1 (en) * | 2019-05-07 | 2022-06-30 | Clexio Biosciences Ltd. | Dosage forms for preventing drug-facilitated assault |
| ES2945809T3 (es) * | 2019-10-02 | 2023-07-07 | Intas Pharmaceuticals Ltd | Composiciones farmacéuticas sólidas efervescentes prácticamente sin sodio |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3412694B2 (ja) * | 1989-10-02 | 2003-06-03 | シーマ・ラブス、インコーポレイテッド | 発泡性投与剤 |
| GB8926612D0 (en) * | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
-
1998
- 1998-12-23 FR FR9816309A patent/FR2787715B1/fr not_active Expired - Lifetime
-
1999
- 1999-12-14 AU AU16639/00A patent/AU1663900A/en not_active Abandoned
- 1999-12-14 WO PCT/FR1999/003120 patent/WO2000038649A1/fr not_active Application Discontinuation
- 1999-12-14 EP EP99959478A patent/EP1140011A1/fr not_active Withdrawn
- 1999-12-22 AR ARP990106668A patent/AR021981A1/es unknown
- 1999-12-22 CO CO99080034A patent/CO5150153A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1663900A (en) | 2000-07-31 |
| FR2787715A1 (fr) | 2000-06-30 |
| FR2787715B1 (fr) | 2002-05-10 |
| WO2000038649A1 (fr) | 2000-07-06 |
| EP1140011A1 (fr) | 2001-10-10 |
| CO5150153A1 (es) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021981A1 (es) | Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero | |
| TR199901077A2 (en) | �spen�iyari form�lasyonlar. | |
| CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
| UY28001A1 (es) | Derivados de azol-pirimidina condensados | |
| DE69925133D1 (de) | Pyrrolobenzodiazepine | |
| BR9810495A (pt) | Composição farmacêutica | |
| DE69934831D1 (de) | MULTIPLEXES, FüR DIE ORALE VERBABREICHUNG GEEIGNETES MEDIKAMENTENABGABESYSTEM | |
| BRPI0414539A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| DK1121127T3 (da) | Orale farmaceutiske sammensætninger, som indeholder buprenorphin | |
| DK0971717T3 (da) | Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler | |
| DK1185253T3 (da) | Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac | |
| AR021934A1 (es) | Composicion de administracion oral con liberacion controlada de al menos un analgesico | |
| ATE321538T1 (de) | Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole | |
| BR0112847A (pt) | Uso de uma forma de dosagem sólida | |
| HN2001000235A (es) | Derivados puentes de piperazina | |
| BR0317623A (pt) | Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram | |
| DE60128100D1 (de) | Analgetisches arzneimittel | |
| ATE353224T1 (de) | Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz | |
| BR9814495A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo | |
| EA200501565A1 (ru) | Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса | |
| UY26224A1 (es) | Complejo farmaceutico ley 17164 art. 127 | |
| AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
| AR029091A1 (es) | Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda) |